GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
U

United Laboratories International Holdings 3933.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

7.91

-0.63%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥15.41bn

FY2016FY2025

Net income

CN¥2.43bn

FY2016FY2025

Free cash flow

CN¥997.9m

FY2016FY2025

Shareholders' equity

CN¥20.30bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥15.41bnCN¥16.05bnCN¥16.03bnCN¥13.22bnCN¥11.32bnCN¥10.23bnCN¥9.79bnCN¥8.76bnCN¥7.96bnCN¥7.09bn
Gross profitCN¥6.43bnCN¥7.09bnCN¥7.39bnCN¥5.80bnCN¥4.91bnCN¥4.44bnCN¥4.22bnCN¥3.56bnCN¥2.91bnCN¥2.52bn
Research and developmentCN¥1.07bnCN¥1.04bnCN¥883.3mCN¥692.4mCN¥542.7mCN¥410.9mCN¥464.9mCN¥365.7mCN¥200.6mCN¥90.0m
Operating incomeCN¥2.65bnCN¥3.64bnCN¥3.84bnCN¥2.35bnCN¥1.65bnCN¥1.44bnCN¥1.19bnCN¥1.05bnCN¥360.8mCN¥388.1m
Net incomeCN¥2.43bnCN¥3.10bnCN¥3.15bnCN¥1.84bnCN¥1.15bnCN¥820.0mCN¥748.6mCN¥796.6mCN¥95.4m−CN¥317.7m
Diluted earnings per share1.251.711.731.010.630.450.460.390.06-0.20

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥36.06bnCN¥30.13bnCN¥24.52bnCN¥22.14bnCN¥19.05bnCN¥17.45bnCN¥18.31bnCN¥17.03bnCN¥16.46bnCN¥17.41bn
Cash and short-term investmentsCN¥13.11bnCN¥7.38bnCN¥4.97bnCN¥5.53bnCN¥3.89bnCN¥3.50bnCN¥3.69bnCN¥1.84bnCN¥1.86bnCN¥2.08bn
Total liabilitiesCN¥15.56bnCN¥13.30bnCN¥9.65bnCN¥9.76bnCN¥8.16bnCN¥7.41bnCN¥10.53bnCN¥9.89bnCN¥10.11bnCN¥11.17bn
DebtCN¥5.83bnCN¥3.16bnCN¥1.50bnCN¥2.46bnCN¥1.84bnCN¥2.21bnCN¥5.00bnCN¥4.25bnCN¥4.86bnCN¥5.88bn
Shareholders' equityCN¥20.30bnCN¥16.78bnCN¥14.85bnCN¥12.37bnCN¥10.90bnCN¥10.05bnCN¥7.78bnCN¥7.14bnCN¥6.35bnCN¥6.24bn
Shares outstanding1,953m1,817m1,817m1,817m1,840m1,838m1,640m2,041m1,627m1,627m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥4.37bnCN¥3.73bnCN¥2.85bnCN¥2.37bnCN¥1.80bnCN¥1.83bnCN¥2.10bnCN¥1.42bnCN¥898.1mCN¥1.25bn
Capital spending−CN¥3.38bn−CN¥2.18bn−CN¥1.71bn−CN¥909.3m−CN¥562.4m−CN¥619.1m−CN¥503.2m−CN¥596.8m−CN¥534.4m−CN¥469.9m
Free cash flowCN¥997.9mCN¥1.55bnCN¥1.14bnCN¥1.46bnCN¥1.24bnCN¥1.21bnCN¥1.60bnCN¥818.4mCN¥363.7mCN¥783.5m
Dividends paid−CN¥1.22bn−CN¥1.19bn−CN¥678.2m−CN¥318.0m−CN¥257.6m−CN¥149.5m−CN¥114.8m−CN¥98.5m−CN¥98.5m−CN¥98.5m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥7.09bnCN¥6.64bnCN¥8.77bnCN¥7.68bnCN¥8.37bnCN¥7.97bnCN¥8.06bnCN¥7.18bn
Gross profitCN¥2.44bnCN¥1.85bnCN¥4.58bnCN¥3.19bnCN¥3.90bnCN¥3.64bnCN¥3.75bnCN¥3.17bn
Operating incomeCN¥642.6m−CN¥21.4mCN¥2.67bnCN¥1.23bnCN¥2.10bnCN¥1.96bnCN¥1.75bnCN¥1.36bn
Net incomeCN¥399.9mCN¥223.5mCN¥2.21bnCN¥1.36bnCN¥1.74bnCN¥1.65bnCN¥1.50bnCN¥1.11bn
Diluted earnings per share0.200.111.130.750.960.910.820.61
Cash from operations—CN¥2.06bnCN¥2.53bnCN¥1.58bnCN¥2.15bnCN¥1.45bnCN¥1.40bnCN¥1.60bn
Capital spending—−CN¥1.33bn−CN¥2.10bn−CN¥1.09bn−CN¥908.0m−CN¥938.0m−CN¥548.0m−CN¥538.0m
Free cash flow—CN¥723.0mCN¥427.0mCN¥488.0mCN¥1.24bnCN¥510.0mCN¥848.0mCN¥1.06bn
Total assetsCN¥37.45bnCN¥36.06bnCN¥34.33bnCN¥30.13bnCN¥26.63bnCN¥24.52bnCN¥23.06bnCN¥22.14bn
Cash and short-term investmentsCN¥13.68bnCN¥13.11bnCN¥10.52bnCN¥7.38bnCN¥7.65bnCN¥4.97bnCN¥5.56bnCN¥5.53bn
DebtCN¥1.38bnCN¥5.83bnCN¥5.98bnCN¥3.68bnCN¥2.87bnCN¥1.75bnCN¥1.78bnCN¥2.87bn
Shareholders' equityCN¥20.08bnCN¥20.30bnCN¥18.16bnCN¥16.78bnCN¥15.78bnCN¥14.85bnCN¥13.45bnCN¥12.37bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin41.7%44.2%46.1%43.8%43.4%43.4%
Operating margin17.2%22.6%23.9%17.8%14.5%14.0%
Net margin15.8%19.3%19.7%13.9%10.2%8.0%
Return on equity12.0%18.5%21.2%14.9%10.6%8.2%
Return on assets6.7%10.3%12.9%8.3%6.1%4.7%
Free cash flow yield44.5%36.5%28.1%20.2%14.4%14.9%
Revenue growth-4.0%0.1%21.2%16.8%10.6%4.5%
Earnings growth-21.6%-1.5%70.9%60.0%40.6%9.5%
Current ratio1.83x1.83x2.08x1.78x1.53x1.69x
Debt to equity0.29x0.22x0.12x0.23x0.20x0.26x
Equity ratio56.3%55.7%60.6%55.9%57.2%57.6%
Interest coverage32.58x89.14x49.17x24.70x23.43x6.79x
R&D as a share of sales7.0%6.5%5.5%5.2%4.8%4.0%
Buybacks as a share of market value-7.5%0.0%0.0%1.2%-0.1%-12.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.2%8.5%7.4%
Operating income4.1%13.0%13.9%
Net income9.7%24.3%36.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.0%44.0%43.8%42.3%
Operating margin20.0%20.5%18.9%15.6%
Net margin17.6%17.3%15.2%11.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings8.16.33.54.26.010.710.89.293.8-23.4
Price to sales1.31.20.70.60.60.90.80.81.11.1

Dividends and splits

Per share, in the currency the company pays

Paid for 8 years. Last went ex-dividend on 7 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.2990.4820.7640.2840.150.1450.0770.068

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.